Search
Now showing items 1-10 of 32
Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells
(2013-06-12)
Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although ...
Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer
(2014-02-01)
Cancer remains one of the major cause of death in the Western world. Although, it has been demonstrated that new therapies can improve the outcome of cancer patients, still many patients relapse after treatment. Therefore, ...
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mtor cascades which alter therapy response
(2012-09-20)
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Certain components of these pathways, RAS, NF1, BRAF, ...
Recent progress in genetics of aging, senescence and longevity: Focusing on cancer-related genes
(2012-12-30)
It is widely believed that aging results from the accumulation of molecular damage, including damage of DNA and mitochondria and accumulation of molecular garbage both inside and outside of the cell. Recently, this paradigm ...
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance
(2012-10-20)
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Targeting these pathways is often complex and can ...
Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia
(2016-08-01)
An attractive molecular target for novel anti-cancer therapies is the
phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR)
pathway which is commonly deregulated in many types of cancer. Nevertheless, ...
Nectin like -5 overexpression correlates with the malignant phenotype in cutaneous melanoma
(2012-08-26)
NECL-5 is involved in regulating cell–cell junctions, in cooperation with cadherins, integrins and platelet-derived growth factor receptor, that are essential for intercellular communication. Its role in malignant ...
Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells
(2014)
Hepatocellular carcinoma (HCC) is characterized by limited response to current
drug therapies. Here, we report that SC66, a novel AKT inhibitor, reduced cell viability
in a dose- and time-dependent manner, inhibited ...
Two hits are better than one: Targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment
(2012-05-04)
Phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) are two key components of the PI3K/Akt/mTOR signaling pathway. This signal transduction cascade regulates a wide range of physiological cell ...